" class="no-js "lang="en-US"> Anat Cohen-Dayag - Medtech Alert
Saturday, September 30, 2023

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Anat Cohen-Dayag

Anat Cohen-Dayag

About Anat Cohen-Dayag

Dr. Anat Cohen-Dayag has over 25 years of experience in the biotech industry, both in R&D and executive leadership roles. Since 2010, Dr. Cohen-Dayag has served as President and CEO of Compugen, a clinical-stage cancer immunotherapy company and a leader in predictive target discovery. Under her leadership, Compugen underwent a strategic transformation to become a therapeutic discovery and development company utilizing its computational discovery expertise to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. Dr. Cohen-Dayag holds an MS in Chemical Immunology and a PhD in Cellular Biology, both from the Weizmann Institute of Science.

Related Story

Appointments

 Compugen Announces Appointment of Alberto Sessa as Chief Financial Officer | Pharmtech Focus

Compugen Announces Appointment of Alberto Sessa as Chief Financial Officer

September 13 2022

Compugen Ltd. ( Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced […]

Diseases

 Compugen's Computational Discovery Leverages Single Cell Spatial Transcriptomics to Gain In-Depth Understanding of the Tumor Microenvironment | Pharmtech Focus

Compugen's Computational Discovery Leverages Single Cell Spatial Transcriptomics to Gain In-Depth Understanding of the Tumor Microenvironment

March 22 2022

Compugen Ltd. (Nasdaq: CGEN), (“Compugen,” the “Company”), a clinical-stage cancer immunotherapy company and a pioneer in computational […]

Fundraising

 Compugen Announces Collaboration Expansion with Bristol Myers Squibb Alongside $20 Million Equity Investment | Pharmtech Focus

Compugen Announces Collaboration Expansion with Bristol Myers Squibb Alongside $20 Million Equity Investment

November 11 2021

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today […]